HK1206266A1 - Methods and compositions for the prevention and treatment neuropathy - Google Patents
Methods and compositions for the prevention and treatment neuropathyInfo
- Publication number
- HK1206266A1 HK1206266A1 HK15106955.3A HK15106955A HK1206266A1 HK 1206266 A1 HK1206266 A1 HK 1206266A1 HK 15106955 A HK15106955 A HK 15106955A HK 1206266 A1 HK1206266 A1 HK 1206266A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prevention
- compositions
- methods
- treatment neuropathy
- neuropathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618428P | 2012-03-30 | 2012-03-30 | |
| PCT/US2013/034647 WO2013149172A1 (en) | 2012-03-30 | 2013-03-29 | Methods and compositions for the prevention and treatment neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206266A1 true HK1206266A1 (en) | 2016-01-08 |
Family
ID=49261299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106955.3A HK1206266A1 (en) | 2012-03-30 | 2015-07-21 | Methods and compositions for the prevention and treatment neuropathy |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9636378B2 (xx) |
| EP (3) | EP3406257B1 (xx) |
| JP (2) | JP6317324B2 (xx) |
| CN (2) | CN107320712A (xx) |
| AU (2) | AU2013237827B2 (xx) |
| CA (1) | CA2869080C (xx) |
| DK (1) | DK2830644T3 (xx) |
| HK (1) | HK1206266A1 (xx) |
| WO (1) | WO2013149172A1 (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2869080C (en) | 2012-03-30 | 2020-09-01 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment neuropathy |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| WO2018034901A1 (en) * | 2016-08-16 | 2018-02-22 | Stealth Biotherapeutics | N-carboxyanhydride-based-scale synthesis of elamipretide |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| CN112961249B (zh) * | 2021-02-25 | 2023-08-04 | 兰州大学 | 一类基于阿片肽和大麻肽的双功能肽及其制备方法与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5913318A (ja) | 1982-07-13 | 1984-01-24 | 株式会社村田製作所 | 電子部品の製造方法 |
| US5786332A (en) * | 1995-03-06 | 1998-07-28 | Trega Biosciences, Inc. | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels |
| US6376467B1 (en) | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| DK2656854T3 (en) * | 2003-02-04 | 2015-07-06 | Cornell Res Foundation Inc | Applications of an aromatic-cationic peptide |
| CN100536909C (zh) * | 2003-02-04 | 2009-09-09 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| CA2851972C (en) * | 2004-01-23 | 2015-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| EP3725324A1 (en) * | 2005-09-16 | 2020-10-21 | Cornell Research Foundation, Inc. | Aromatic-cationic peptide for use in a method for reducing cd36 expression |
| SI2252312T1 (sl) | 2008-02-07 | 2014-08-29 | Cornell University, | Postopki za preprečevanje ali zdravljenje insulinske rezistence |
| WO2009108695A2 (en) * | 2008-02-26 | 2009-09-03 | Cornell University | Methods for prevention and treatment of acute renal injury |
| US20100331265A1 (en) * | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
| HUE029550T2 (en) * | 2009-08-12 | 2017-03-28 | Univ Cornell | Methods of preventing or treating metabolic syndrome |
| PT2470191E (pt) * | 2009-08-24 | 2014-06-12 | Stealth Peptides Int Inc | Métodos e composições para prevenção ou tratamento de doenças oftálmicas |
| CN102711785A (zh) * | 2009-10-05 | 2012-10-03 | 康奈尔大学 | 预防或治疗心力衰竭的方法 |
| EP2519249A4 (en) * | 2009-12-31 | 2013-06-26 | Stealth Peptides Int Inc | METHODS OF REALIZING AORTO-CORONARY BRIDGE |
| US20130195837A1 (en) * | 2009-12-31 | 2013-08-01 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| AU2011207432A1 (en) * | 2010-01-25 | 2012-08-02 | Cornell University | Aromatic-cationic peptides and uses of same |
| US20130040901A1 (en) * | 2010-02-26 | 2013-02-14 | University Of Florida Research Foundation Inc. | Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy |
| EP3560508A1 (en) * | 2010-03-15 | 2019-10-30 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| US9345738B2 (en) * | 2010-07-09 | 2016-05-24 | Stealth Biotherapeutics Corp. | Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury |
| US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
| KR101351432B1 (ko) | 2011-12-27 | 2014-01-15 | 에스케이씨 주식회사 | 초미세 발포 폴리우레탄 탄성체의 제조방법 |
| CA2869080C (en) | 2012-03-30 | 2020-09-01 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment neuropathy |
-
2013
- 2013-03-29 CA CA2869080A patent/CA2869080C/en active Active
- 2013-03-29 JP JP2015503653A patent/JP6317324B2/ja active Active
- 2013-03-29 AU AU2013237827A patent/AU2013237827B2/en active Active
- 2013-03-29 US US14/388,705 patent/US9636378B2/en active Active
- 2013-03-29 EP EP18169371.4A patent/EP3406257B1/en active Active
- 2013-03-29 DK DK13769696.9T patent/DK2830644T3/en active
- 2013-03-29 CN CN201710226838.6A patent/CN107320712A/zh active Pending
- 2013-03-29 CN CN201380023997.6A patent/CN104271146A/zh active Pending
- 2013-03-29 EP EP16192386.7A patent/EP3170506B1/en active Active
- 2013-03-29 WO PCT/US2013/034647 patent/WO2013149172A1/en active Application Filing
- 2013-03-29 EP EP13769696.9A patent/EP2830644B1/en active Active
-
2015
- 2015-07-21 HK HK15106955.3A patent/HK1206266A1/xx unknown
-
2017
- 2017-04-17 US US15/488,697 patent/US10279008B2/en active Active
- 2017-11-21 AU AU2017265013A patent/AU2017265013B9/en active Active
-
2018
- 2018-03-29 JP JP2018063574A patent/JP2018123143A/ja active Pending
-
2019
- 2019-04-22 US US16/390,799 patent/US10646539B2/en active Active
-
2020
- 2020-04-07 US US16/842,040 patent/US20200397850A1/en not_active Abandoned
-
2022
- 2022-03-01 US US17/684,057 patent/US11998585B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10279008B2 (en) | 2019-05-07 |
| US20150087595A1 (en) | 2015-03-26 |
| JP2018123143A (ja) | 2018-08-09 |
| AU2017265013A1 (en) | 2017-12-07 |
| US20200397850A1 (en) | 2020-12-24 |
| AU2017265013B9 (en) | 2019-05-02 |
| US20220296672A1 (en) | 2022-09-22 |
| EP2830644B1 (en) | 2016-11-16 |
| CN104271146A (zh) | 2015-01-07 |
| AU2013237827A1 (en) | 2014-10-16 |
| EP2830644A1 (en) | 2015-02-04 |
| US20190343913A1 (en) | 2019-11-14 |
| CN107320712A (zh) | 2017-11-07 |
| CA2869080C (en) | 2020-09-01 |
| US10646539B2 (en) | 2020-05-12 |
| EP3170506B1 (en) | 2018-05-16 |
| EP3406257A1 (en) | 2018-11-28 |
| DK2830644T3 (en) | 2017-02-27 |
| EP3170506A1 (en) | 2017-05-24 |
| JP6317324B2 (ja) | 2018-04-25 |
| US9636378B2 (en) | 2017-05-02 |
| CA2869080A1 (en) | 2013-10-03 |
| AU2013237827B2 (en) | 2017-12-14 |
| WO2013149172A1 (en) | 2013-10-03 |
| JP2015512420A (ja) | 2015-04-27 |
| US11998585B2 (en) | 2024-06-04 |
| EP3406257B1 (en) | 2020-04-22 |
| US20170340695A1 (en) | 2017-11-30 |
| EP2830644A4 (en) | 2015-10-21 |
| AU2017265013B2 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
| HK1214521A1 (zh) | 用於治療蛋白質病的組合物和方法 | |
| HK1216009A1 (zh) | 前列環素組合物及其使用方法 | |
| EP2861256A4 (en) | COMPOSITIONS FOR THE TREATMENT OF CANCER AND METHODS FOR PREPARING THE SAME | |
| HK1251796A1 (zh) | 治療糖尿病的方法和組合物 | |
| EP2875359A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES | |
| ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| HK1209633A1 (en) | Compositions and methods for treating diabetes | |
| EP2897613A4 (en) | TREATMENT COMPOSITIONS | |
| HK1216250A1 (zh) | '- '-羥基-二氫麥角胺化合物及組合物 | |
| HK1206266A1 (en) | Methods and compositions for the prevention and treatment neuropathy | |
| GB201315350D0 (en) | Methods and compositions | |
| HK1212366A1 (en) | Textile treatment compounds and compositions | |
| GB201315347D0 (en) | Methods and compositions | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| EP2931280A4 (en) | METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1 | |
| ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
| EP2834635A4 (en) | COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR | |
| IL235312A0 (en) | Taxane compounds, preparations and methods | |
| EP2800763A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | |
| GB201222736D0 (en) | Composition and process |